Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration

The collaboration leverages Remix's REMaster™ platform to discover novel drugs for a diverse range of target classes "Completing this milestone further demonstrates the power and potential of the REMaster platform, purposebuilt to identify novel, druggable RNA processing mechanisms," said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix. "We are incredibly proud of the research team's accomplishments, which bring us closer towards potentially developing new, small molecule medicines for p ...